PSTV 株価分析 — PLUS THERAPEUTICS INC (Healthcare >> Biotechnology)
PSTV に関するよくある質問
PSTVのPER(株価収益率)は?
PLUS THERAPEUTICS INC(PSTV)は現在PER 4.88倍で取引されています。
PSTVのROE(自己資本利益率)は?
PLUS THERAPEUTICS INCのROEは-99.75%です。
PSTVの配当利回りは?
PLUS THERAPEUTICS INCの配当利回りは0.00%です。
PSTVの品質スコア(Quality Score)は?
当社のAIはPSTVの総合財務品質を100点中31点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
PSTVは今が買い時ですか?
当社AIのタイミングスコアは100点中27点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
PSTVはどのセクターに属しますか?
PLUS THERAPEUTICS INCはHealthcare >> Biotechnologyセクターに分類されます(NASDAQ市場)
PSTV AI Analysis Summary
Our AI summary for PSTV: PLUS THERAPEUTICS INC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 4.88, ROE of -99.75%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 3.87
Price
0.22
(6.03%)
Day Change
|
|
|---|
PSTV, ファンダメンタルスコアはnot good ( ファンダメンタル = 31) そして テクニカルスコアは ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
48% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 88 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 3.87 |
| PBV / Sector |
2.10 / 5.20
|
| Earning Per Share | -1.84 |
| PE / Sector |
4.88 / 19.97
GREAT
|
| PEG or PE/Growth / Sector |
-0.06 / 1.22
|
| Average 1M Daily Value |
0.46 M
GREAT
|
| Average 1W Daily Value |
0.26 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
41% |
| ポイントになる統計 |
|
47% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:21 |
| Symbol | PSTV |
| Name | PLUS THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 6.88 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 25.13 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 6420 LEVIT GREEN BOULEVARD, Houston, TX, United States, 77021
Phone: 737 255 7194
Website: https://plustherapeutics.com
Sector: Healthcare >> Biotechnology
Description: Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests comprising the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
Google